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Abstract
Yuan et al. recently described an independent evaluation of several phenotype-driven gene prioritization methods for Mendelian
disease on two separate, clinical datasets. Although they attempted to use default settings for each tool, we describe three key
differences from those we currently recommend for our Exomiser and PhenIX tools. These inf luence how variant frequency, quality
and predicted pathogenicity are used for filtering and prioritization. We propose that these differences account for much of the
discrepancy in performance between that reported by them (15–26% diagnoses ranked top by Exomiser) and previously published
reports by us and others (72–77%). On a set of 161 singleton samples, we show using these settings increases performance from 34%
to 72% and suggest a reassessment of Exomiser and PhenIX on their datasets using these would show a similar uplift.
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We were pleased to see the recent publication in this
journal on phenotype-driven gene prioritization methods
for Mendelian disease [1]. This evaluation of the methods
on two real clinical datasets (N = 305 and 209) will be
welcomed by the clinical genetics community, especially
as it is performed by an independent group that have
not been involved in developing any of the assessed
tools. However, we were surprised by the reported figures
for our Exomiser tool, e.g. 15% and 26% of diagnoses
identified as the top ranking hits in their two datasets
compared with 38–58% for AMELIE, xRare and LIRICAL.
As reported recently, we have used Exomiser to identify
77% of diagnoses as the top-ranking candidate for
the 100 000 Genomes Project and this has led to its
adoption in the Genomic Medicine Service of the UK
National Health Service [2]. Similarly, for a retinal disease
dataset 74% of diagnoses were ranked first by Exomiser
[3] and a completely independent group from the Los
Angeles Children Hospital reported a performance
of 72% [4].
The authors state that default settings were used for
each assessed software, but a closer inspection of the
settings used by them when assessing Exomiser 12.1.0
revealed three key differences from those we routinely

use. Here, we investigated whether these differences
are likely to account for the above discrepancies. On a
set of 161 diagnosed singleton cases from the 100 000
Genomes project (100KGP), using the same Exomiser
version (12.1.0) they tested, we observe that 34% are
identified as the top candidate with their settings versus
72% with ours. Incrementally reintroducing our settings
to theirs highlights the differences these make:
(1) Including mode of inheritance (MOI) specific frequency filtering (0.1% for dominant or homozygous
recessive modes, 2% for compound-heterozygous,
recessive) increases performance to 44%. This is the
recommended default in the version of Exomiser
12.1.0 they assessed and is closer to the minor
allele frequency (MAF) filtering settings used for
the higher performing tools in their hands such as
LIRICAL and AMELIE. Note this filter, as used in
the default recommendation, runs every possible
MOI using appropriate MAF settings rather than
restricting to preselected modes of inheritance that
may not be known ahead of analysis.
(2) Including the failedFrequencyFilter further increases
performance to 62%. This setting filters out any
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low-quality variants that are not f lagged as PASS
in the FILTER column of the VCF file. The settings
Yuan et al. [1] used for LIRICAL and AMELIE did
include filtering of non-PASS variants and this likely
explains much of the improved performance they
reported for these tools. Although this filter was
documented in the example settings for Exomiser
12.1.0 it was not explicitly stated as a default
recommendation. Since release 13 of Exomiser
(September 2021) this is explicitly specified in the
preset options.
(3) Using REVEL and MVP as more modern sources of
predicted pathogenicity data than Polyphen2, MutationTaster and SIFT further increases performance
to 72%. Again, although REVEL and MVP were available for the version of Exomiser tested (12.1.0), they
were not clearly f lagged as default settings but since
release 13 they are now in the recommended preset
options.
Figure 1 summarizes these results alongside the previously reported performance of Exomiser on clinical
datasets.
In conclusion, we recommend all users to use the
preset options provided in Exomiser, or if they are
altering configuration to make sure that the above
three options are retained for optimal performance:

e.g. the provided example VCF file (Pfeiffer.vcf.gz)
and clinical data (pfeiffer-phenopacket.yml) will run
with these recommended settings if simply run as
java -jar exomiser-cli-13.0.1.jar—sample examples/
pfeiffer-phenopacket.yml—vcf examples/Pfeiffer.vcf.gz—
assembly hg19. PhenIX, another tool they assessed, runs
as part of the Exomiser framework and will similarly
benefit from using these recommended settings. We
suspect that most, if not all, of the differences in
performance the authors observe between xRare, AMELIE
and LIRICAL and Exomiser/PhenIX are due to these
variant filtering settings rather than the underlying gene
prioritization algorithms they set out to evaluate. We
would be very interested to see if this is the case in a
future assessment of their datasets.
Key Points
• Variant filtering settings, as well as phenotype similarity approaches, are critical for the performance of
phenotype-driven gene prioritization approaches.
• Mode of inheritance specific frequency and variant quality filtering alongside use of REVEL and MVP are the
latest recommended options for Exomiser and PhenIX.
• Use of these latest recommended settings, versus those
used in the study of Yuan et al., increased detection of the
diagnosis as the top-ranked candidate from 34% to 72%
in our hands.
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Figure 1. Performance of Exomiser on clinical datasets reported in previous studies [1–4] and here [100KGP] using various settings.
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